Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(4):439-451
Objective. To develop criteria for the interpretation and quality assurance of the results of susceptibility testing of Enterobacterales and P. aeruginosa to cefepime-sulbactam.
Materials and Methods. The study included 1035 clinical Enterobacterales isolates and 407 P. aeruginosa isolated in 2023 from hospitalized patients with nosocomial and community-acquired infections. Determination of cefepime and cefepime-sulbactam MICs was performed by broth microdilution method in Mueller-Hinton II broth in accordance with ISO 20776 1:2019.